FDA drafts guidance on genome editing, CAR T cell therapies
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsNorth AmericaProduct LifecycleRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesBiotechnologyChemistry, Manufacturing and Controls (CMC)Clinical TrialsNorth AmericaProduct Lifecycle